In This Article:
Apollo Technology Capital, which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs (MEDIF), owning approximately 3% of the Company’s common stock, issued anurgent warning to shareholders, regulators, and the investing public concerning allegations of alleged securities act disclosure violations committed by MediPharm Labs’ Board of Directors and management team. Apollo said, “Apollo Capital has received alarming reports from multiple highly credible and independent sources revealing that MediPharm Labs allegedly engaged in deliberate, systematic financial misfeasance and deceptive accounting practices aimed at grossly misleading investors and artificially inflating the Company’s reported revenues and stock valuation. Such allegations represent blatant violations of securities laws, fiduciary obligations, and ethical business conduct, potentially exposing MediPharm and its Board to serious legal and financial consequences. Given the grave seriousness and substantial credibility of these allegations, Apollo Capital urgently demands an immediate, robust investigation by regulatory authorities including the Ontario Securities Commission, the Toronto Stock Exchange, and the U.S. Securities and Exchange Commission. Apollo Capital further insists that MediPharm’s Board of Directors immediately cooperate fully with all regulatory investigations, transparently disclose all related information, and suspend any management or Board members implicated in these serious allegations pending investigation outcomes. Apollo Capital has received credible information regarding these allegations directly from a current MediPharm Labs Board member, specifically implicating MediPharm’s Chairman, Chris Taves, Managing Director and Head of Capital Markets for Asia at BMO and a CPA, in orchestrating schemes to intentionally overstate Company revenues. It is curious that starting recently, Chris Taves serves as both the Board Chair and the Audit Committee Chair. Sources allege that MediPharm engaged partners in deceptive practices to artificially boost revenue reporting, misleading investors into perceiving growth where none truly existed. Apollo Capital demands to know if this is the reason that Michael Bumby just stepped down as Audit Committee Chair and has not stood for re-election to the MediPharm Board…Apollo Capital directly challenges each MediPharm Board member-Shelley Potts, Michael Bumby, Chris Halyk, Chris Taves, Keith Strachan, and David Pidduck-to publicly address these allegations openly and transparently. Apollo Capital reiterates its repeated calls for full disclosure, particularly emphasized in its press release asking about these misfeasance allegations before MediPharm’s Q1 earnings call and its follow-up press release highlighting the Company’s disastrous financial performance and refusal to answer shareholder questions. Any Board member failing to acknowledge and publicly address these allegations will be perceived as complicit in the alleged misfeasance.”